Unrelated stem cell transplantation for severe acquired aplastic anemia: Improved outcome in the era of high-resolution HLA matching between donor and recipient

Haematologica

Volumn 92, Issue 5, 2007, Pages 589-596

  Maury, Sébastien ^a   Balère Appert, Marie Lorraine ^b   Chir, Zina ^c   Boiron, Jean Michel ^d   Galambrun, Claire ^e   Yakouben, Karima ^f   Bordigoni, Pierre ^g   Marie Cardine, Aude ^h   Milpied, Noel ^i,k   Kanold, Judith ^j   Maillard, Natacha ^i,k   Socié, Gérard ^l  

^a HENRI MONDOR HOSPITAL   (France)

^b France Greffe de Moelle (FGM)   (France)

^c Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM TC)   (France)

^d HAUT LÉVÊQUE HOSPITAL   (France)

^e HÔPITAL DEBROUSSE   (France)

^f HÔPITAL ROBERT DEBRÉ   (France)

^g CHU NANCY BRABOIS   (France)

^h HÔPITAL CHARLES NICOLLE   (France)

ⁱ HÔTEL DIEU   (France)

^j HÔTEL DIEU   (France)

^k HÔPITAL NECKER ENFANTS MALADES   (France)

^l SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

Aplastic anemia; Hla matching; Prognostic factors; Volunteer donors

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; DRUG DERIVATIVE; FLUDARABINE; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; VIDARABINE;

ADOLESCENT; ADULT; ALLELE; APLASTIC ANEMIA; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; FRANCE; GRAFT RECIPIENT; HLA SYSTEM; HUMAN; INFANT; MULTIVARIATE ANALYSIS; NEWBORN; ORGAN DONOR; OUTCOME ASSESSMENT; REGISTER; STEM CELL TRANSPLANTATION; SURVIVAL; ALLOTRANSPLANTATION; CAUSE OF DEATH; CHI SQUARE DISTRIBUTION; COHORT ANALYSIS; COMPARATIVE STUDY; EVALUATION; FEMALE; GENETICS; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; LIVING DONOR; LYMPHOCYTE DEPLETION; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NONPARAMETRIC TEST; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; REOPERATION; RETROSPECTIVE STUDY; STATISTICS; SURVIVAL RATE; T LYMPHOCYTE; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; ANTILYMPHOCYTE SERUM; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINURIA, PAROXYSMAL; HEPATITIS; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; KAPLAN-MEIERS ESTIMATE; LIVING DONORS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REOPERATION; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; SURVIVAL RATE; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE;

EID: 34447334234     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10899     Document Type: Article

References (30)

1. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006;108:2509-19.
2. Horowitz MM. Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol 2000;37:30-42.
3. Kojima S, Hibi S, Kosaka Y, Yamamoto M, Tsuchida M, Mugishima H, et al. Immunosuppressive therapy using antithymocyte globulin, cyctosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood 2000;96:2049-54.
4. Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogt HG, Herrmann F, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med 1991;324:1297-304.
5. Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 2000;95:1931-4.
6. Margolis DA, Casper JT. Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia. Semin Hematol 2000;37:43-55.
7. Bacigalupo A, Hows J, Gordon-Smith EC, Gluckman E, Van Lint MT, Congiu M, et al. Bone marrow transplantation for severe aplastic anemia from donors other than HLA identical siblings: a report of the BMT Working Party. Bone Marrow Transplant 1988;3:531-5.
8. Hows J, Szydlo R, Anasetti C, Camitta B, Gajewski J, Gluckman E. Unrelated donor marrow transplants for severe acquired aplastic anemia. Bone Marrow Transplant 1992;10 Suppl 1:102-6.
9. Passweg JR, Perez WS, Eapen M, Camitta BM, Gluckman E, Hinterberger W, et al. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant 2006;37:641-9.
10. Deeg HJ, O'Donnell M, Tolar J, Agarwal R, Harris RE, Feig S, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 2006; 108:1485-91.
11. Kojima S, Matsuyama T, Kato S, Kigasawa H, Kobayashi R, Kikuta A, et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood 2002;100:799-803.
12. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825-8.
13. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-A-matched sibling donors. Transplantation 1974;18:295-304.
14. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
15. Deeg HJ, Seidel K, Casper J, Anasetti C, Davies S, Gajeweski JL, et al. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant 1999; 5: 243-52.
16. Ades L, Mary JY, Robin M, Ferry C, Porcher R, Esperou H, et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood 2004;103:2490-7
17. Petersdorf EW. Immunogenomics of unrelated hematopoietic cell transplantation. Curr Opin Immunol 2006;18:1-6.
18. Kojima S, Yabe H, Kato K, Kigasawa H, Sakamaki H, Tsuchida M, et al. Effects of HLA-C and HLA-DQB1 Mismatching on outcome of unrelated donor marrow transplantation for patients with severe aplastic anemia. ASH Annual Meeting Abstracts 2005; 106:563.
19. Niederwieser D, Pepe M, Storb R, Loughran TP Jr, Longton G. Improvement in rejection, engraftment rate and survival without increase in graft-versus-host disease by high marrow cell dose in patients transplanted for aplastic anaemia. Br J Haematol 1988;69:23-8.
20. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98:2942-7.
21. Bacigalupo A, Locatelli F, Lanino E, Marsh J, Socie G, Maury S, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant 2005;36:947-50.
22. Srinivasan R, Takahashi Y, McCoy JP, Espinoza-Delgado I, Dorrance C, Igarashi T, et al. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br J Haematol 2006; 133:305-14.
23. Storb R, Leisenring W, Anasetti C, Appelbaum FR, Buckner CD, Bensinger WI, et al. Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. Blood 1997;89:3890-1.
24. Bordin JO, Heddle NM, Blajchman MA. Biologic effects of leukocytes present in transfused cellular blood products. Blood 1994;84:1703-21.
25. Passweg JR, Socie G, Hinterberger W, Bacigalupo A, Biggs JC, Camitta BM, et al. Bone marrow transplantation for severe aplastic anemia: has outcome improved? Blood 1997; 90: 858-64.
26. Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P, et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2005;36:757-69.
27. Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004;103:3979-81.
28. Bacigalupo A, Oneto R, Bruno B, Socie G, Passweg J, Locasciulli A, et al. Current results of bone marrow transplantation in patients with acquired severe aplastic anemia. Report of the European Group for Blood and Marrow transplantation. On behalf of the Working Party on Severe Aplastic Anemia of the European Group for Blood and Marrow Transplantation. Acta Haematol 2000;103:19-25.
29. Deeg HJ, Amylon ID, Harris RE, Collins R, Beatty PG, Feig S, et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 2001;7:208-15.
30. Marsh JC, Ball SE, Darbyshire P, Gordon-Smith EC, Keidan AJ, Martin A, et al. Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol 2003;123:782-801.